Quantus

Precigen

PGEN-US · Nasdaq
$6.27+5.56%
2026-07-31 close

Precigen — pricey right now, or cheap? And what signals are flashing today?

Open the exact grade & valuation bands with Pro →
Loading chart…
CloseMA20MA60MA120
AI Insight

Why these signals fired — only backtest-proven edge, told honestly

Why this signalSignal guide

Moving-average alignment
Yes · score 0.85
Explore this stock further
Review signal, financial and filing context in chat
Explore in chat →

Strong-buy signal — the real recordrecord · not a prediction

Not this one stock, but every strong-buy pick we actually published (US market). When this stock flashes the signal, it is treated by the same rule.(as of 2026-08-03)

Last 30 sessions
759 picks
Next-day win rate
58.8%
Avg next-day
+0.55%
vs market
+0.45%p

Beat the market on 57.6% of picks (each pick vs its own day’s market average).

Recent publish days (next-day win rate)
07-30 27.3%07-29 30.8%07-28 11.1%07-27 50%07-24 28.6%07-23 44.4%07-22 50%07-21 60%07-20 33.3%07-17 37.5%07-16 16.7%07-15 50%
This stock flashed this signal 1 time over the last ~2 years (see the signal history below for each date).

Entry is the latest close at publish time; next-day is the following close. “Market” is the equal-weighted average of every stock in the same market that day; delisted names are excluded from both. Fees, taxes and slippage are not included. An observed record over a short window, not a pre-registered backtest. Not investment advice.

Valuation Grades

Relative to 759 건강관리 peers · not investment advice

Pro unlocks the composite grade, 5 factors and sector rank · ₩19,900/mo

Valuation in its own history

PER — · PBR 33.25 — own history (2013-08~) percentiles 63/100 · 0/100

PER63/100
PBR0/100

Higher indicates lower valuation relative to its history (based on earnings and book yields).

Earnings percentiles can fluctuate for cyclical companies (including loss periods), so the book basis is shown alongside. Companies with large share buybacks can have structurally high PBR. Factual information, not investment advice.

Financial safety

Reference indicatorAs of 2024
Distress zoneFinancial-metric reference signal
Altman Z'' zoneZ'' -48.62
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
-48.62
Beneish M-Score
-5.26

No statistical flag

Sloan accrual
-39.97%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Why has this company moved this way?

Auditable observations with the original numeric evidence.

매출 하락 → 마진 압박 → 현금 악화

Critical

매출이 -36.9% 감소하며 영업이익률이 -1601.6%에서 -3440.2%로 하락했다. 영업현금흐름도 동반 감소하여 수익-현금 순환이 약화되고 있다.

Evidence

매출 YoY -36.9% (2023→2024)영업이익률 -1601.6%→-3440.2%영업CF -67→-68

차입 증가 → 이자부담 → 수익성 악화

Critical

부채가 +141.3% 늘며 이자보상배율이 -213.0x에서 -22504.8x로 하락했다. ROE도 -84.1%에서 -202.3%로 낮아져 차입 부담이 수익성을 누르고 있다.

Evidence

부채 YoY +141.3%이자보상배율 -213.0x→-22504.8xROE -84.1%→-202.3%

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

2/9Weak

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score2/9

Profitability

  • Positive ROANot passed
  • Positive OCFNot passed
  • Improving ΔROANot passed
  • Accruals (OCF > net income)Pass

Leverage & liquidity

  • Lower debtNot passed
  • Higher current ratioPass
  • No new sharesNot passed

Efficiency

  • Higher gross marginNot passed
  • Higher asset turnoverNot passed

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Forensic signals

Anomaly and structural signals observed in the financial statements.

Revenue qualityDanger

매출 흑자인데 영업CF 적자 (OCF/매출 -1737%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Revenue qualityWarning

OCF/매출 3기 연속 하락. 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Balance sheetWarning

부채총계 급증 (+141%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Margin trendWarning

영업이익률 악화 (-1601.6% → -3440.2%, -1838.7%p). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Factual information, not investment advice.

Industry structure

USAs of 2026-08-03

건강관리

This stock is in 건강관리: revenue rank 460 of 553, share 0%.

460 / 5530%revenue share

Who dominates this industry?

  1. 1CVS Health14.1%
  2. 2McKesson13.6%
  3. 3Cigna9.4%
  4. 4Cardinal Health8.4%
  5. 5Centene6.2%
  6. 6Precigen0%

Concentration

DistributedCR3 37.1%
HHI 642553 revenue members

HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.

Polarization

Winner-take-all deepeningConsistent

Polarization measures industry gaps and structure, not valuation, forecast, or investment advice.

Margin lens

IQR%p
159.97
Direction
축소
Level
넓음
Years
22

Value lens

P90/P10
23.8
Median P/B
3.07
Level
넓음
n
467

Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
-3,440.2%
Interest coverage
-22,504.8x
Return on equity (ROE)
-189.2%

Operating margin −5pp

Operating loss
Interest coverageBase -22,504.8x adverse case -22,537.5x
Return on equity (ROE)Base -189.2% adverse case -202.7%

Revenue −15%

Interest coverage risk
Interest coverageBase -22,504.8x adverse case -19,129.1x
Return on equity (ROE)Base -189.2% adverse case -172%

Interest rate +2pp

Interest coverage risk
Interest coverageBase -22,504.8x adverse case -85.6x
Return on equity (ROE)Base -189.2% adverse case -204.7%

Interest coverage limit

Already below the limit by 3,440.4pp

Interest coverage limit at an operating margin of 0.2%

Interest expense coverage threshold

Financials at a glance

Precigen's latest results and balance sheet. The bars track the last three periods.

Connections

AI-extracted related companies · for reference

🔗 See in the full market map →

📦 ETFs holding this stock

by weight · top-10 constituents basis

Passive money holding this stock ≈ $1M(lower bound — top-10 basis, not a forecast)

Factual holdings info from daily disclosures — not a recommendation.

Look up another stock →

Recent filings

Filings for overseas stocks are on the way. For now we cover Korean stocks only.

Signal history (last ~2 years)

Every occurrence on this stock, with the return 20 trading days later. Small sample — a record, not a prediction.

Strong buy (52w high + volume)×1
26-06-26-7.5%
52-week high breakout×4
26-07-31·26-06-29-6.6%26-06-26-7.5%26-06-25-2.2%
New MA alignment×4
26-07-30·26-07-28·26-07-08·26-06-22+2%

“·” = fewer than 20 trading days since the event. Cup-and-handle entries are days our board actually showed the badge (archive grows daily since 2026-05-12); others are recomputed from price data.

Like these rules? Run them automatically.

Quantus turns rules like these into backtests and automated trading — same team, free to start.

Quantus Signal · live data · not investment advice · Privacy Policy